Israeli psychedelic drug developer Clearmind Medicine has signed an agreement with Polyrizon for development of an intranasal formulation of Clearmind’s 5‑methoxy‑2‑aminoindane (MEAI) based on Polyrizon’s intranasal hydrogel technology, the companies said. According to Clearmind, MEAI is a non-hallucinogenic neuroplastogen that the company is developing for the treatment of conditions such as weight loss and addiction.
In March 2025, Polyrizon announced that that it had signed an agreement with an unidentified company that specializes in psychedelic therapies for development of a nasal formulation of a psychedelic therapy. According to Clearmind’s press release regarding the new agreement, “Polyrizon is a related party . . . and the entering into of this arrangement is a related party transaction.”
Polyrizon’s hydrogel platform for drug delivery is called Trap and Target. The company is also developing its Capture and Contain hydrogel as a “biological mask” to shield the nasal cavity against infection and in September 2025 announced that the submission of a pre-submission package to the FDA for its PL-14 Allergy Blocker nasal spray.
Clearmind CEO Adi Zuloff-Shani commented, “We are pleased to partner with Polyrizon to develop an intranasal formulation for MEAI. Their advanced hydrogel platform complements our efforts to optimize delivery, potentially improving bioavailability and therapeutic efficacy, and patient experience for our non-hallucinogenic neuroplastogen candidates. We believe that this agreement reflects Clearmind’s proactive approach to innovative collaborations that accelerate progress and address unmet needs in addiction and mental health disorders.”
Polyrizon CEO Tomer Izraeli said, “We are proud to collaborate with Clearmind on the development of an intranasal formulation of MEAI. Our proprietary intranasal technology is designed to enable more targeted, efficient delivery, and we believe it may offer meaningful value as Clearmind advances MEAI through its clinical pathway. We believe that this agreement reflects Polyrizon’s growing role as a partner of choice for companies seeking specialized intranasal drug‑delivery expertise.”
Read the Polyrizon press release
Read the Clearmind press release
